KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Equity Average (2018 - 2025)

Historic Equity Average for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$442.4 million.

  • Esperion Therapeutics' Equity Average fell 2385.7% to -$442.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$442.4 million, marking a year-over-year decrease of 2385.7%. This contributed to the annual value of -$421.9 million for FY2024, which is 833.93% down from last year.
  • Esperion Therapeutics' Equity Average amounted to -$442.4 million in Q3 2025, which was down 2385.7% from -$429.9 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Equity Average high stood at -$182.8 million for Q1 2021, and its period low was -$442.4 million during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was -$333.5 million (2021), whereas its average is -$336.3 million.
  • Its Equity Average has fluctuated over the past 5 years, first tumbled by 172785.23% in 2021, then soared by 1226.21% in 2024.
  • Esperion Therapeutics' Equity Average (Quarter) stood at -$279.8 million in 2021, then dropped by 10.4% to -$308.9 million in 2022, then plummeted by 39.99% to -$432.5 million in 2023, then grew by 12.26% to -$379.5 million in 2024, then dropped by 16.59% to -$442.4 million in 2025.
  • Its last three reported values are -$442.4 million in Q3 2025, -$429.9 million for Q2 2025, and -$407.5 million during Q1 2025.